Ballentine Partners, LLC Innoviva, Inc. Transaction History
Ballentine Partners, LLC
- $6.57 Billion
- Q2 2025
A detailed history of Ballentine Partners, LLC transactions in Innoviva, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 17,426 shares of INVA stock, worth $350,088. This represents 0.01% of its overall portfolio holdings.
Number of Shares
17,426Holding current value
$350,088% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding INVA
# of Institutions
273Shares Held
78MCall Options Held
2.3KPut Options Held
2.4K-
Black Rock Inc. New York, NY9.63MShares$193 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.18MShares$144 Million0.0% of portfolio
-
Putnam Investments LLC Boston, MA6.27MShares$126 Million0.14% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.76MShares$95.6 Million0.14% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.29MShares$86.3 Million0.02% of portfolio
About Innoviva, Inc.
- Ticker INVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 69,706,000
- Market Cap $1.4B
- Description
- Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...